Evidence investigation
Ask PeptideBlog about any peptide
A real research program. An oral triple-agonist connection. One important missing piece: the exact molecule behind the code.
A development code can become searchable long before its chemistry becomes clear. LY4086940 is a case in point: the documents are real, the research trail is growing, and the full molecular identity is still difficult to pin down.
That creates a tempting shortcut: find a related peptide, borrow a molecular weight, and fill the empty fields. The result looks technical. The central identification problem remains.
The information gap invites confident guesses. A better approach is to ask what each document can establish, and what would be needed to connect the documents to one another.
Update, October 26: the Phase 2 site list
ClinicalTrials.gov now lists 46 sites for the Phase 2 study, NCT07890376: 39 in the United States and 7 in Argentina (six in Buenos Aires and one in Rosario). The study is not yet recruiting, with a listed start in November 2026. It plans 460 adults aged 18 to 75 who have obesity, or overweight with a weight-related health condition, and no diabetes, and it compares LY4086940 with placebo. The main measure is percent change in body weight at week 32, with week 48 as a secondary measure. Participation is listed at about 58 weeks, and the listed primary completion date is January 2028. The record sits under Lilly’s master protocol for weight-management studies, NCT06143956.
The listing does not state the drug’s mechanism, structure or doses, and it has no posted results. A site list shows where Lilly plans to enroll. It does not show that dosing has started.
Start with three separate evidence questions
| Question | Evidence needed |
|---|---|
| Is there a clinical program? | A sponsor-submitted registry entry or equivalent original documentation |
| What class or mechanism is proposed? | A sponsor disclosure or original pharmacology report clearly tied to the program |
| What is the exact molecule? | A complete chemical specification explicitly assigned to the development code |
One source may answer the first question well and leave the third untouched. That does not make the source useless. It means its scope has limits.
What the clinical records establish
The Phase 1 record, NCT06945419, describes oral cohorts and a separate IV cohort; 219 participants were enrolled, and completion was August 5, 2026. A new Phase 2 record, NCT07890376, appeared October 22. Neither record reviewed contains posted results. [1,2]
Phase 1
- Status
- Completed
- Enrolled
- 219
- Completion
- August 5, 2026
- Results posted
- None
Phase 2
- Status
- Not yet recruiting
- Planned enrollment
- 460
- Listed start
- November 2026
- Listed sites
- 46
- Results posted
- None
Values as listed on ClinicalTrials.gov. A registration is not a result, and a listed start date is not evidence that dosing has begun.
Those entries support the existence of a human research program. They do not supply a public sequence or turn a development code into a usable chemical reference.
Readers can follow changes through the clinical trial tracker, then inspect the original registration. A status change, an amended endpoint, and a published result should be described separately.
Why the peptide classification has a credible basis
Lilly’s Q4 2025 presentation places LY4086940 under “GGG Tri-Agonist III.” Its ADA presentation separately names an oral GGG peptide with GLP-1, GIP, and glucagon receptor targets. The combined evidence strongly supports the program connection, but does not disclose the exact chemistry. [3,4]
That is an evidence-based inference with a clear boundary. It should not be inflated into a sequence assignment. Nor should a generic “small molecule” description outrank more specific original sponsor materials without explanation.
Classification, mechanism, and identity are connected questions, not interchangeable ones.
The molecular-weight question exposes the problem
What is the molecular weight of LY4086940? In the public sources reviewed for this article, it remains unverified.
A precise-looking number is tempting because it makes a technical profile feel complete. Yet a number can be copied accurately from the wrong molecule. Until the underlying chemical identity is established, additional decimal places do not resolve the uncertainty.
The same applies to a molecular formula, a structural drawing, or a sequence presented without its original assignment. The important question is where the connection to LY4086940 was documented.
What a patent can reveal, and what it cannot settle alone
Relevant Lilly publications include WO2024163535A1 and US20240270821A1, titled “GIP/GLP1/GCG tri-receptor agonists and uses thereof.” They disclose peptide examples and oral-delivery work. No example-to-LY4086940 assignment was established in this review. [5,6]
A patent can therefore provide structures worth investigating while leaving the clinical-candidate question open. Selecting one example because its mechanism sounds right would be a hypothesis, not a verified identification.
The missing bridge could appear in a later publication, a protocol appendix, a sequence disclosure, or another original document. The format matters less than an explicit, traceable connection.
A purity percentage answers a different question
Suppose a laboratory report shows a prominent chromatographic peak. That may help characterize the sample under the stated method. It does not, by itself, assign the peak to a development code.
Purity and identity are different analytical questions. Evaluating them requires attention to what was measured, what reference information was used, and how the interpretation follows from the results.
Our guide to reading a peptide COA explains why the scope of a test report matters. A development program with unresolved public chemistry is a particularly poor place to treat a label as proof.
Why oral administration leaves another layer unresolved
Even after identity is established, the formulation question remains. An oral clinical intervention is more than the name of an active ingredient. The public record would need to explain the relevant formulation before outside readers could assess what has actually been tested.
The available information does not justify assigning a specific capsule design, absorption enhancer, numerical bioavailability, or food restriction to LY4086940. Evidence from another peptide or another patent example cannot fill those fields automatically.
This is why “a capsule containing the same named compound” and “the studied clinical formulation” should never be treated as equivalent without supporting evidence.
An evidence checklist for the next disclosure
A useful new source should help answer at least one of these questions:
- Identity: Does it explicitly connect the development code with a complete structure?
- Traceability: Can the assignment be followed back to an original document?
- Specificity: Are the findings about LY4086940 itself, rather than the wider drug class?
- Results: Does it report measured outcomes, or only describe planned work?
- Formulation: Does it identify what was administered, beyond the active-ingredient name?
The next useful headline should come from one of those answers.
Questions readers are asking
What is GGG Tri-Agonist III?
It is the program name Lilly uses in its Q4 2025 earnings slides for the study titled as a trial of LY4086940, so the sponsor itself connects the two names. [3] A separate Lilly ADA slide lists an oral GGG peptide with GLP-1, GIP and glucagon receptor targets. [4] Neither slide discloses a sequence, formula, dose or results, and no slide states outright that the two entries are the same compound.
Is a verified LY4086940 CAS number available?
No public assignment was verified in the sources reviewed here. That is a search finding, not proof that no assignment exists anywhere.
Has its full sequence been established publicly?
This review did not establish one. A sequence from a plausible patent needs an explicit connection before it can be presented as the candidate’s sequence.
Is it the same molecule as retatrutide?
The sponsor lists distinct programs. An overlapping receptor concept does not establish chemical equivalence. [4]
What would justify updating this article?
A traceable identity disclosure, new original data, or a substantive change in the clinical record. Generic commentary alone would not resolve the central questions.
For LY4086940, the next important development may be a small technical detail: a structure, sequence, or explicit cross-reference. Until then, the most informative answer to an unresolved field is an honest one.
Independent educational reporting. This article provides no purchasing, dosing, administration, or self-experimentation guidance. Registry entries document research; they do not establish approval, safety, or efficacy. The artwork is conceptual.
Related reading on LY4086940
- LY4086940 profile on PeptideBlog, the quick-reference entry with the registry facts, what has not been disclosed, and the compare pages against retatrutide and orforglipron.
- LY4086940 timeline, the public record of the program in date order, from the 2024 patent context to the October 2026 phase 2 registration.
- Trial Tracker, where both registered LY4086940 trials are listed with their current status.
- The Weight Loss Atlas: LY4086940, a plain-language page on the two registered trials and what is not yet public.
- Lilly’s LY numbers explained, what the LY codes in trials and papers mean and which ones match a public name.
- The Weight Loss Atlas pipeline tracker, where LY4086940 sits among weight-management medicines in phase 1 to 3 trials.
- EloralintideResearch.com: what the two LY4086940 trial records show, a reading of the same records with an evidence tag on each statement.
- Retzoundi and Retkouro, the Lilly trademark filings people are searching for, and how names in a filing differ from development codes such as LY4086940.
